Rapid vaccine and therapeutic platforms
Going from a pathogen sequence to a distributed vaccine or antibody in weeks rather than years.
State of the art
2020 mRNA vaccine development from sequence to clinical dosing in 65 days; the 100 Days Mission sets the current target; designed-protein antigens and binders from computational pipelines are now in clinical use.
- Manufacturing and fill-finish surge capacity, not design, sets the real timeline
- Antigen design for engineered or immune-evasive pathogens cannot be validated without the pathogen
- Regulatory review, trial enrollment and global distribution dominate the schedule after the first dose exists
Who’s working on it
- CEPI ↗Program
Owns the 100 Days Mission target, ran an April 2026 Disease X platform call with awards up to 5 million dollars, and is seeking 2.5 billion for its 2027 to 2031 strategy
- International Pandemic Preparedness SecretariatProgram
Published its fourth annual 100 Days Mission implementation report in January 2026, finding encouraging progress but significant remaining work
- ModernaCompany
Went from published sequence to first-in-human dosing in about 65 days in 2020 and remains the reference implementation of a rapid mRNA platform
- Kizzmekia Corbett-HelaireResearcherHarvard T.H. Chan School of Public Health
Co-designed mRNA-1273 from sequence at the NIH Vaccine Research Center and now runs a coronavirus vaccine and therapeutic antibody design lab
- University of OxfordAcademic lab
Holds a CEPI award of up to 80 million dollars for rapid-response vaccine platform development, the main non-mRNA route to the 100-day target
- BioNTechCompany
The other mRNA platform proven at pandemic scale, now building regional manufacturing capacity, which is the real constraint on surge response
What to invest in
| Kind | Investment | Scale |
|---|---|---|
| infrastructure | Standing warm-base manufacturing capacity, distributed regionally, with pre-qualified fill-finish lines | $$$$ > $1B |
| policy | Pre-agreed trial protocols, platform-technology regulatory pathways and allocation agreements that can be triggered on day one | $$ $10M – $100M |
Depends on
Required by
No other capability builds on this directly.